You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康緣藥業(600557.SH):南京康竹擬增持3423萬元公司股份
格隆匯 02-24 16:59

格隆匯2月24日丨康緣藥業(600557.SH)公佈,根據公司收購江蘇中新醫藥有限公司(簡稱“中新醫藥”)100%股權所簽訂《股權轉讓協議》《股權轉讓協議之補充協議》中對賭條款的約定,中新醫藥原股東南京康竹企業管理合夥企業(有限合夥)(簡稱“南京康竹”)取得其持有中新醫藥30%股權的首筆股權轉讓款扣除應繳納稅費後的剩餘資金,即34,229,986.06元,全部用於二級市場擇機增持我公司股份。中新醫藥股權轉讓交割先決條件已滿足,公司已向南京康竹支付首筆股權轉讓款,並書面同意南京康竹自2025年2月24日至2025年3月25日在二級市場擇機增持我公司股份。南京康竹成立於2024年5月,其成立目的系作爲中新醫藥管理層及核心團隊之股權激勵平臺。南京康竹此次增持公司股份,系看好公司未來發展前景,將自身利益與中新醫藥研發管線藥品的上市進程深度綁定,激勵核心團隊積極推進藥品研發與上市工作,與公司共享未來收益,共擔未來風險,進一步維護上市公司及中小投資者的利益。

2025年2月24日,南京康竹通過上海證券交易所交易系統以集中競價交易方式增持了公司股份185,200股,佔公司總股本的0.03%。南京康竹擬自2025年2月24日起30日內,通過上海證券交易所交易系統以集中競價或大宗交易方式擇機增持公司無限售條件流通A股股份。本次增持計劃不設定價格區間,擬增持金額爲34,229,986.06元(含本次已增持金額,因市場股價波動,實際交易中可能出現剩餘金額不足以購買一手的情況,導致擬增持金額未完全用於購買公司股份,公司已充分知悉並不會追究增持主體因此產生的責任)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account